 AstraZeneca PLC LSE:AZN will spend up to US320mln to strengthen its cancer business with an acquisition specialising in an innovative cell therapy approach for hard-to-treat cancers. Amsterdam-based Neogene Therapeutics Inc focuses on next-generation T-cell receptor therapies TCR-Ts to treat patients with advanced solid tumours. 